NasdaqGS - Nasdaq Real Time Price USD

Terns Pharmaceuticals, Inc. (TERN)

Compare
6.73 +0.14 (+2.12%)
At close: December 13 at 4:00:01 PM EST
6.92 +0.19 (+2.81%)
After hours: 7:43:44 PM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
1,000.00
--
Operating Expense
99,980.00
102,558.00
62,029.00
50,860.00
37,025.00
Operating Income
-99,980.00
-102,558.00
-62,029.00
-49,860.00
-37,025.00
Net Non Operating Interest Income Expense
12,479.00
12,901.00
2,110.00
170.00
55.00
Other Income Expense
-303.00
-314.00
-68.00
40.00
-2,788.00
Pretax Income
-87,804.00
-89,971.00
-59,987.00
-49,650.00
-39,758.00
Tax Provision
269.00
239.00
358.00
508.00
813.00
Net Income Common Stockholders
-88,073.00
-90,210.00
-60,345.00
-50,158.00
-29,352.00
Diluted NI Available to Com Stockholders
-88,073.00
-90,210.00
-60,345.00
-50,158.00
-29,352.00
Basic EPS
-1.18
-1.27
-1.67
-2.21
-1.29
Diluted EPS
-1.18
-1.27
-1.67
-2.21
-1.29
Basic Average Shares
74,762.14
71,259.24
36,033.05
22,705.95
22,721.72
Diluted Average Shares
74,762.14
71,259.24
36,033.05
22,705.95
22,721.72
Total Operating Income as Reported
-99,980.00
-102,558.00
-62,029.00
-49,860.00
-37,025.00
Total Expenses
99,980.00
102,558.00
62,029.00
50,860.00
37,025.00
Net Income from Continuing & Discontinued Operation
-88,073.00
-90,210.00
-60,345.00
-50,158.00
-40,053.00
Normalized Income
-88,073.00
-90,210.00
-60,345.00
-50,158.00
-40,053.00
Interest Income
12,479.00
12,901.00
2,110.00
170.00
55.00
Net Interest Income
12,479.00
12,901.00
2,110.00
170.00
55.00
EBIT
-99,980.00
-102,558.00
-62,029.00
-49,860.00
-37,025.00
EBITDA
-99,078.00
-101,677.00
-60,997.00
-49,348.00
-36,631.00
Reconciled Depreciation
902.00
881.00
1,032.00
512.00
394.00
Net Income from Continuing Operation Net Minority Interest
-88,073.00
-90,210.00
-60,345.00
-50,158.00
-40,053.00
Normalized EBITDA
-99,078.00
-101,677.00
-60,997.00
-49,348.00
-36,631.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 2/5/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers